MX2010006995A - 3-n-fenil-1,3,4-oxadiazolonas sustituidas con 5-o para uso medico. - Google Patents

3-n-fenil-1,3,4-oxadiazolonas sustituidas con 5-o para uso medico.

Info

Publication number
MX2010006995A
MX2010006995A MX2010006995A MX2010006995A MX2010006995A MX 2010006995 A MX2010006995 A MX 2010006995A MX 2010006995 A MX2010006995 A MX 2010006995A MX 2010006995 A MX2010006995 A MX 2010006995A MX 2010006995 A MX2010006995 A MX 2010006995A
Authority
MX
Mexico
Prior art keywords
phenyl
substituted
oxadiazolones
medical use
oxadiazolone
Prior art date
Application number
MX2010006995A
Other languages
English (en)
Inventor
David Alexander Learmonth
Laszlo Erno Kiss
Humberto Dos Santos Ferreira
Patricio Manuel Vieira Araujo Soares Da Silva
Alexander Beliaev
Original Assignee
Bial Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bial Portela & Ca Sa filed Critical Bial Portela & Ca Sa
Publication of MX2010006995A publication Critical patent/MX2010006995A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)

Abstract

La presente invención se refiere a compuestos que tienen una unidad estructural de 3-N-fenil-l,3,4-oxadiazolona sustituida con 5-0, que tienen un nivel inesperadamente alto de inhibición de FAAH (hidrolasa de amida de ácido graso). (Fórmula (I)). (Ver fórmula I).
MX2010006995A 2007-12-27 2008-12-23 3-n-fenil-1,3,4-oxadiazolonas sustituidas con 5-o para uso medico. MX2010006995A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US930207P 2007-12-27 2007-12-27
PCT/PT2008/000054 WO2009084970A1 (en) 2007-12-27 2008-12-23 5-o-substituted 3-n-phenyl-1,3,4-oxadiazolones for medical use

Publications (1)

Publication Number Publication Date
MX2010006995A true MX2010006995A (es) 2010-08-18

Family

ID=40361548

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006995A MX2010006995A (es) 2007-12-27 2008-12-23 3-n-fenil-1,3,4-oxadiazolonas sustituidas con 5-o para uso medico.

Country Status (14)

Country Link
EP (1) EP2238131A1 (es)
JP (1) JP2011507952A (es)
KR (1) KR20100111691A (es)
CN (1) CN101959881A (es)
AR (1) AR069970A1 (es)
AU (1) AU2008344032A1 (es)
BR (1) BRPI0821482A2 (es)
CA (1) CA2710743A1 (es)
CL (1) CL2008003895A1 (es)
IL (1) IL206419A0 (es)
MX (1) MX2010006995A (es)
TW (1) TW200932732A (es)
WO (1) WO2009084970A1 (es)
ZA (1) ZA201005306B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010074587A2 (en) * 2008-12-23 2010-07-01 Bial - Portela & Ca., S.A. 5-o-substituted 3-n-aryl-1,3,4-oxadiazolones for medical use
AR076687A1 (es) * 2009-05-18 2011-06-29 Infinity Pharmaceuticals Inc Isoxazolinas como inhibidores de la amidahidrolasa de acidos grasos y com-posiciones farmaceuticas que los contienen
WO2010151160A1 (en) * 2009-06-24 2010-12-29 Bial - Portela & Ca., S.A. O-substituted 3-n-heteroaryl-1,3,4-oxadiazolones for medical use
WO2011085216A2 (en) 2010-01-08 2011-07-14 Ironwood Pharmaceuticals, Inc. Use of faah inhibitors for treating parkinson's disease and restless legs syndrome
US20130224151A1 (en) 2010-03-31 2013-08-29 United States Of America Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931843A1 (de) * 1989-09-23 1991-04-04 Bayer Ag Substituierte 1,3,4-oxa(thia)diazolinone verfahren zu ihrer herstellung und ihre verwendung der bekaempfung von endoparasiten
DE19942354A1 (de) * 1999-09-04 2001-03-08 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxdiazol-2-one, ihre Herstellung und Verwendung in Arzneimitteln
AU2002347985A1 (en) * 2001-11-15 2003-06-10 Eli Lilly And Company Peroxisome proliferator activated receptor alpha agonists
DE10208987A1 (de) * 2002-02-28 2003-09-11 Aventis Pharma Gmbh Substituierte 3-Phenyl-5-alkoxi-1,3,4-oxidiazol-2-one, ihre Herstellung und Verwendung in Arzneistoffen
US20090111778A1 (en) * 2005-11-18 2009-04-30 Richard Apodaca 2-Keto-Oxazoles as Modulators of Fatty Acid Amide Hydrolase

Also Published As

Publication number Publication date
IL206419A0 (en) 2010-12-30
CA2710743A1 (en) 2009-07-09
WO2009084970A1 (en) 2009-07-09
TW200932732A (en) 2009-08-01
AU2008344032A1 (en) 2009-07-09
JP2011507952A (ja) 2011-03-10
AU2008344032A8 (en) 2010-08-19
ZA201005306B (en) 2011-04-28
EP2238131A1 (en) 2010-10-13
CN101959881A (zh) 2011-01-26
CL2008003895A1 (es) 2010-06-25
BRPI0821482A2 (pt) 2015-07-14
KR20100111691A (ko) 2010-10-15
AR069970A1 (es) 2010-03-03

Similar Documents

Publication Publication Date Title
UA104010C2 (en) Purine compounds
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
NZ585460A (en) Inhibitors of human phosphatidyl-inositol 3-kinase delta
TN2009000509A1 (en) Pyrazole carboxylic acid amides useful as microbiocides
HK1136283A1 (en) Compounds for the prevention and treatment of cardiovascular diseases
MX2010007952A (es) Arilpirrolinas insecticidas.
UA105229C2 (uk) Фармацевтичний склад
MY151295A (en) Pyrimidyl indoline compound
UA102817C2 (ru) Способ синтеза агомелатина
MX2012003982A (es) Pirrolidinas n-substituidas.
ZA200806778B (en) N-Hydroxyacrylamide compounds
TW200745097A (en) 4-Phenyl-thiazole-5-carboxylic acids and 4-phenyl-thiazole-5-carboxylic acid amides as PLK1 inhibitors
MX2012004780A (es) Inhibidores de akt.
UA102220C2 (ru) Способ синтеза агомелатина
MX2011011776A (es) Nuevos profarmacos de triptolite.
WO2008053334A3 (en) An improved process for preparing rosuvastatin calcium
MX2010010877A (es) Compuestos y composiciones como inhibidores de itpkb.
MX2010006995A (es) 3-n-fenil-1,3,4-oxadiazolonas sustituidas con 5-o para uso medico.
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
MX2012007426A (es) Derivados de amino-heteroarilo como bloqueadores de los canales activados por la hiperpolarizacion, controlados por nucleotidos ciclicos.
WO2011047055A3 (en) Novel mek inhibitors, useful in the treatment of diseases
WO2009097973A3 (de) Imidazopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel
MY145122A (en) Phenylacetic acid derivatives as cox-2 inhibitors
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
WO2010103273A3 (en) Essential fatty acid compounds

Legal Events

Date Code Title Description
FA Abandonment or withdrawal